Sterculia 62% granules 7g sachets gluten free
Karaya gum allergenic extract is used in allergenic testing.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Sterculia
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
8 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · 2019–2026
Showing the 50 most relevant studies, sorted by most relevant.
Wisdom Ahlidja, Elvis Fiam Amegayibor, Lily Addae, et al.
Scientific African, 2024
Yuan L, Shu B, Zhou J, et al.
2026
BackgroundPlant seeds constitute an important category of medicinal and edible herbs. However, assessments regarding their safety for human consumption remain insufficient. This systematic review comprehensively evaluates human safety for 21 medicinal and edible seeds.MethodsTwo independent reviewers screened the titles, abstracts, and fulltexts of the retrieved literature against the inclusion and exclusion criteria to identify eligible AE reports in both English (PubMed, Embase, CENTRAL) and Chinese (CNKI, Wanfang, VIP, SinoMed) databases. Search strategies were constructed using the scientific names, common names, and frequent aliases of the medicinal and edible seeds combined with safety evaluation keywords such as "adverse reaction," "toxicity," and "side effect." Any studies describing adverse event (AE) after human intake of specific seeds were included. AE characteristics were summarized. Causality between seed consumption and AEs was assessed.ResultsWe identified 703 AEs involving eight medicinal and edible seeds. Ginkgo semen and Armeniacae semen amarum caused the most AEs, followed by Persicae semen, Myristicae semen, Sterculiae lychnophorae semen, Canavaliae semen, Cassiae semen, and Ziziphi spinosae semen. Among the AEs, 70.8% occurred in children, and 68.9% were associated with excessive intake. Most AEs manifested as gastrointestinal and/or neurological symptoms. Ninety-six were classified as serious; these were caused by Ginkgo semen (29 cases), Armeniacae semen amarum (60 cases), Persicae semen (4 cases), Canavaliae semen (2 cases), and Myristicae semen (1 case). These SAEs resulted in 15 fatalities and 3 cases of permanent functional impairment. Causality with seed consumption was determined to be "certain" for 239 AEs, "probable" for 449, and "possible" for 15. No AE reports were found for thirteen seeds.ConclusionConsuming specific medicinal and edible seeds, particularly Ginkgo semen, Armeniacae semen amarum, Persicae semen, Myristicae semen, and Canavaliae semen, poses potential risks, including fatal cases. Excessive dosages, consumption by children, and inappropriate processing were primary causes. Therefore, strengthening safety management for these is warranted.Protocol registrationPROSPERO (No. CRD42023426497).
Abstract licence: CC BY-NC-ND
N. Bhanu Teja, Y. Devarajan, Ruby Mishra, et al.
Biomass Conversion and Biorefinery, 2021
Lu Wang, Yuan Yan, Yi‐Meng Hao, et al.
Chemistry & Biodiversity, 2024
- Sterculia
- Phytochemicals
- Anti-Inflammatory Agents
Mery Rambu, B. Djoru, Samatcha Krungkaew, et al.
ASEAN Journal of Scientific and Technological Reports, 2026
Y. Devarajan, C. D.
Results in Engineering, 2024
Mamta Dhiman, Abhijeet Singh, M. Sharma
Industrial Crops and Products, 2019
Siswadi Siswadi, G. Saragih
INTERNATIONAL CONFERENCE ON LIFE SCIENCES AND TECHNOLOGY (ICoLiST 2020), 2021
Julia Ferreira Da Silva, A. C. de Jesus Oliveira, M. F. de La Roca Soares, et al.
International journal of biological macromolecules, 2021
- Drug Delivery Systems
- Sterculia
- Biocompatible Materials
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
ATC A06AC03
ATC A06AC53
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Karaya gum
Matched from: Sterculia
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72